Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Pioglitazone/Metformin After Intensive Insulin in Newly Diagnosed T2D
NCT03196362Phase 4Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pioglitazone and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Remission rate at 48 weeks. Status: unknown.
02
Drugs
pioglitazoneliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03196362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196362.